Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

1.

The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.

Levy AG, Zage PE, Akers LJ, Ghisoli ML, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin AR, Huang P, Zweidler-McKay PA.

Invest New Drugs. 2012 Feb;30(1):191-9. doi: 10.1007/s10637-010-9551-y. Epub 2010 Oct 5.

PMID:
20890785
[PubMed - indexed for MEDLINE]
2.

Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin.

Akers LJ, Fang W, Levy AG, Franklin AR, Huang P, Zweidler-McKay PA.

Leuk Res. 2011 Jun;35(6):814-20. doi: 10.1016/j.leukres.2010.12.028. Epub 2011 Feb 12.

PMID:
21316758
[PubMed - indexed for MEDLINE]
3.

Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.

Biochem Pharmacol. 2012 May 1;83(9):1146-58. doi: 10.1016/j.bcp.2012.01.013. Epub 2012 Jan 20.

PMID:
22285225
[PubMed - indexed for MEDLINE]
4.

Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.

Li Z, Yan S, Attayan N, Ramalingam S, Thiele CJ.

Clin Cancer Res. 2012 Jul 1;18(13):3603-15. doi: 10.1158/1078-0432.CCR-11-3321. Epub 2012 May 1.

PMID:
22550167
[PubMed - indexed for MEDLINE]
Free Article
5.

FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.

Fang L, Wang H, Zhou L, Yu D.

Toxicol Appl Pharmacol. 2011 Feb 15;251(1):8-15. doi: 10.1016/j.taap.2010.11.007. Epub 2010 Nov 16.

PMID:
21092744
[PubMed - indexed for MEDLINE]
6.

A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.

Zage PE, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV, Zweidler-McKay PA.

Cancer. 2010 May 15;116(10):2465-75. doi: 10.1002/cncr.25017.

PMID:
20225331
[PubMed - indexed for MEDLINE]
Free Article
7.

Effective elimination of cancer stem cells by a novel drug combination strategy.

Yuan S, Wang F, Chen G, Zhang H, Feng L, Wang L, Colman H, Keating MJ, Li X, Xu RH, Wang J, Huang P.

Stem Cells. 2013 Jan;31(1):23-34. doi: 10.1002/stem.1273.

PMID:
23132831
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.

Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, Demartines N, Dormond O.

BMC Cancer. 2012 Mar 8;12:86. doi: 10.1186/1471-2407-12-86.

PMID:
22401294
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.

Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P.

Leukemia. 2005 Dec;19(12):2153-8.

PMID:
16193082
[PubMed - indexed for MEDLINE]
10.

Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.

Bhola P, Banerjee S, Mukherjee J, Balasubramanium A, Arun V, Karim Z, Burrell K, Croul S, Gutmann DH, Guha A.

Int J Cancer. 2010 Jan 15;126(2):563-71. doi: 10.1002/ijc.24783.

PMID:
19634141
[PubMed - indexed for MEDLINE]
11.

Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma.

Lee SC, Marzec M, Liu X, Wehrli S, Kantekure K, Ragunath PN, Nelson DS, Delikatny EJ, Glickson JD, Wasik MA.

NMR Biomed. 2013 Jan;26(1):106-14. doi: 10.1002/nbm.2825. Epub 2012 Jun 18.

PMID:
22711601
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.

Huang JJ, Li ZM, Huang Y, Huang Y, Tian Y, He XX, Xiao J, Lin TY.

Invest New Drugs. 2012 Feb;30(1):223-35. doi: 10.1007/s10637-010-9558-4. Epub 2010 Oct 20.

PMID:
20960030
[PubMed - indexed for MEDLINE]
13.

Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy.

Anandharaj A, Cinghu S, Park WY.

Acta Biochim Biophys Sin (Shanghai). 2011 Apr;43(4):292-300. doi: 10.1093/abbs/gmr012. Epub 2011 Mar 1.

PMID:
21367753
[PubMed - indexed for MEDLINE]
14.

mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.

Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.

Anticancer Res. 2008 Nov-Dec;28(6A):3801-8.

PMID:
19189667
[PubMed - indexed for MEDLINE]
Free Article
15.

Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.

Nagata Y, Takahashi A, Ohnishi K, Ota I, Ohnishi T, Tojo T, Taniguchi S.

Int J Oncol. 2010 Oct;37(4):1001-10.

PMID:
20811722
[PubMed - indexed for MEDLINE]
16.

Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.

Wang X, Zhan Y, Zhao L, Alvarez J, Chaudhary I, Zhou BB, Abraham RT, Feuerstein GZ.

J Pharmacol Exp Ther. 2011 Nov;339(2):421-9. doi: 10.1124/jpet.111.185249. Epub 2011 Aug 11.

PMID:
21835932
[PubMed - indexed for MEDLINE]
Free Article
17.

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.

Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T.

Mol Cancer Ther. 2011 Jun;10(6):1059-71. doi: 10.1158/1535-7163.MCT-10-0792. Epub 2011 Apr 11.

PMID:
21482695
[PubMed - indexed for MEDLINE]
Free Article
18.

Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.

Itamochi H, Oishi T, Shimada M, Sato S, Uegaki K, Naniwa J, Sato S, Nonaka M, Terakawa N, Kigawa J, Harada T.

Clin Cancer Res. 2011 Jul 15;17(14):4742-50. doi: 10.1158/1078-0432.CCR-11-0190. Epub 2011 May 24.

PMID:
21610153
[PubMed - indexed for MEDLINE]
Free Article
19.

Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.

Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, Piccardi F, Cilli M, Di Paolo D, Pagnan G, Longo L, Perri P, Ribatti D, Ponzoni M.

Clin Cancer Res. 2007 Jul 1;13(13):3977-88.

PMID:
17606732
[PubMed - indexed for MEDLINE]
Free Article
20.

Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.

Liu J, Kuo WL, Seiwert TY, Lingen M, Ciaccio MF, Jones RB, Rosner MR, Cohen EE.

Head Neck. 2011 Dec;33(12):1774-82. doi: 10.1002/hed.21701. Epub 2011 Mar 24.

PMID:
21438065
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk